LEONARDO GOMES DA FONSECA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - S(a)over-tildeo Paulo Clinicas Liver Cancer Group Multidisciplinary Consensus Statement (vol 75, e2192, 2020)(2021) ABADALA, Edson; CHAGAS, A. L.; FONSECA, L. G. da; COELHO, F. F.; SAUD, L. R. C.; ABADALA, E.; ANDRAUS, W.
- An infectious etiology of esophageal cancer spreading from endemic to non-endemic areas(2021) FONSECA, Leonardo G. da; HASHIZUME, Pedro H.
- Neoadjuvant and adjuvant systemic treatment for hepatocellular carcinoma(2021) MATHIAS-MACHADO, Maria Cecilia; FONSECA, Leonardo G. daHepatocellular carcinoma (HCC) is a highly lethal malignancy, and few patients are candidates for curative-intended therapies. The mainstay of curative treatment in HCC is surgical resection, ablation, and transplantation. However, rates of recurrence are high, and there is no established approach to reduce the risk of recurrence and mortality. We discuss the available data and current landscape of (neo)adjuvant therapies aimed at decreasing recurrence risk and improving overall survival, including liver-directed therapies, tyrosine kinase inhibitors, and immunotherapy. Neoadjuvant strategies aimed at downstaging advanced HCC to enable local treatment and minimize the risk of recurrence using novel agents are also a topic of interest in current research. The improvements achieved in the advanced stages with immune-checkpoint inhibitors are priming ongoing trials that address potential future directions for both adjuvant and neoadjuvant strategies that may change the treatment paradigm of HCC in the near future.
- Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma-ready for their use?(2021) FONSECA, Leonardo Gomes Da; FORNER, Alejandro
conferenceObject Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters(2021) MUNOZ-MARTINEZ, Sergio; SAPENA, Victor; FORNER, Alejandro; BRUIX, Jordi; ZAMPARELLI, Marco Sanduzzi; BOUATTOUR, Mohamed; LEAL, Cassia Regina Guedes; THEODORO, Carmem Ferguson; EL-KASSAS, Mohammed; NAULT, Jean Charles; BLAISE, Lorraine; MOCAN, Tudor; FONSECA, Leonardo Gomes da; REEVES, Helen L.; ALVES, Rogerio; JUAREZ, Ignacio Garcia; VARELA, Maria; PINATO, David J.; GARDINI, Andrea Casadei; ALVARES-DA-SILVA, Mario Reis; SANTIAGO, Jesus Gonzalez; LOZANO, Maria del Mar; BANDI, Juan Carlos; RIMASSA, Lorenza; SALA, Margarita; ALQAHTANI, Saleh; ANDERS, Maria Margarita; PINERO, Federico; LACHENMAYER, Anja; TACKE, Frank; RODERBURG, Christoph; GOMEZ, Manuel Romero; PECK-RADOSAVLJEVIC, Markus; CABIBBO, Giuseppe; ELVEVI, Alessandra; GUARINO, Maria; FRANCA, Alex Vianey Callado; VILLANI, Rosanna; GOMEZ, Mercedes Vergara; ACEVEDO, Juan; LOPE, Carlos Rodriguez de; MELLO, Vivianne; PERELLO, Christie; PASCUAL, Sonia; BRACONI, Chiara; IAVARONE, Massimo; REIG, Maria- Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma(2021) MARTA, Guilherme Nader; FONSECA, Leonardo G. da; BRAGHIROLI, Maria Ignez; MOURA, Fernando; HOFF, Paulo M.; SABBAGA, JorgeOBJECTIVES: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). METHODS: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the local institutional protocol. Patients were divided into two groups, Group A, individuals <70 years of age, and Group B, individuals 70 years of age or older at the time of treatment initiation. Efficacy, measured based on overall survival (OS) and time to treatment failure (TTF), and toxicity were compared between groups. RESULTS: A total of 238 patients with advanced HCC who received sorafenib between 2007 and 2018 were evaluated. The median age for Group A was 59.1 years and that for Group B 73.6 years. The major prognostic characteristics were balanced between the groups. There were no significant differences in OS between Group A (8.0 months, 95%Cl 6.34-9.3) and Group B (9.0 months, 95%CI 5.38-12.62), p=0.433, or in TTF between Group A (3.0 months, 95%CI 2.39-3.60) and Group B (3.0 months, 95%CI 1.68-4.32), p=0.936. There were no significant differences between Groups A and B with respect to the incidence of adverse events or treatment discontinuation because of toxicity. CONCLUSION: Efficacy and safety of sorafenib did not differ significantly between younger and older patients with HCC. Our data suggest that age alone should not restrict clinical decision-making for patients with advanced HCC.